Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Protagonist Therapeutics announced that its senior management team will participate in four upcoming investment bank conferences throughout November 2026.
UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $184.
Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.